Introduction
The reciprocal translocation t(8;21)(q22;q22) is one of the most frequent chromosomal aberrations in acute myeloblastic leukemia (AML). 1, 2 This aberration results in the fusion of two genes, AML1 on chromosome 21 and MTG8 on chromosome 8, leading to the AML1/MTG8 fusion gene on the derivative chromosome 8 and the transcription of a chimeric AML1/MTG8 fusion mRNA. 3, 4 Since the breakpoints of this chromosomal aberration cluster within the same intron, 5 identical AML1/MTG8 fusion transcripts can be detected by RT-PCR in all patients with t(8;21).
In t (8;21) positive AML patients usually a high complete remission rate can be achieved by a standard induction Correspondence: G Heil, Dept of Hematology and Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; Fax: 49 511 532 3611 Received 6 July 1999; accepted 20 October 1999 chemotherapy while the long-term prognosis of these particular patients still remains unclear. [6] [7] [8] [9] The detection of AML1/MTG8 by RT-PCR has been used to monitor the leukemic burden during and after chemotherapy with the aim of identifying patients with a high risk of relapse. However, using qualitative RT-PCR, several groups have shown that the vast majority of t(8;21) patients treated with conventional chemotherapy or even autologous or allogeneic stem cell transplantation consistently have detectable levels of AML1/MTG8 fusion transcripts thus questioning the prognostic value of these analyses. [10] [11] [12] [13] [14] [15] [16] Preliminary data indicate that quantitative RT-PCR techniques are suitable to determine the chemosensitivity of the leukemic clone and to predict a relapse in these patients. [17] [18] [19] The quantification strategy of competitive PCR is based on the co-amplification of an internal RNA or DNA standard molecule of different size or with an additional restriction site. 20 Though competitive RT-PCR is time consumptive and needs further processing after amplification, it is widely used and validated for the quantification of specific DNA or RNA targets in hematological and infectious diseases. [21] [22] [23] [24] Recently, real time PCR, a new quantitative PCR method based on the 5Ј-3Ј exonuclease activity of the Taq DNA-polymerase and a fluorescence energy transfer, was introduced. 25, 26 This method is increasingly used for the quantification of fusion transcripts in a wide variety of hematological diseases. [27] [28] [29] [30] [31] In contrast to competitive PCR, this technique uses standard curves derived from the amplification of an external standard, which is carried out in separate PCR tubes, for quantification. 32, 33 It is therefore not clear if results obtained by competitive or real-time PCR can be directly compared. To further analyze this problem, we compared the sensitivity, linearity and reproducibility of real-time PCR with that of an optimized nested competitive RT-PCR assay for the detection and quantification of AML1/MTG8 fusion transcripts.
Patients and methods

Cell lines
The t(8;21) positive AML cell line Kasumi-1 34 and the promyelocytic cell line NB4 35 were obtained from the German Col- 
Kasumi-1 dilution series
Kasumi-1 cells were serially diluted in t(8;21) negative NB4 cells from 1:0 to 1:10 5 . Total cellular RNA was extracted from 10 7 cells of this dilution series using the Trizol-method (Gibco BRL) according to the manufacturer's guidelines. cDNA was synthesized for 1 h at 37°C using 2 g RNA, random primers (1 mol/l) and murine Moloney virus reverse transcriptase in a total volume of 20 l.
Patient samples
After informed consent was given, bone marrow samples were taken from three patients with t(8;21) positive AML at initial diagnosis (у80% blasts in the bone marrow) and at various time points during/after chemotherapy. Prior to analysis, the mononuclear cells were enriched by a Ficoll-Isopaque gradient (1077 g/ml). RNA extraction and cDNA synthesis were performed as described above.
Quantitative competitor PCR Competitor construction:
A 338 bp RT-PCR product spanning the AML1/MTG8 breakpoint was generated by amplification of cDNA from the t(8;21) positive Kasumi-1-cell line as described. 36 This PCR product was extracted from an agarose gel and cloned into the pCR 2.1 vector (Invitrogen, Carlsbad, CA, USA). A 42 bp DNA fragment, generated by digestion of the pBluescript SK (+/−) vector with SacI and SmaI was cloned into the HpaI site of the AML1/MTG8 sequence of this construct. This resulted in a DNA competitor molecule 42 base pairs longer than the wild-type AML1/MTG8 sequence ( Figure 1a) . Sequencing of the vector construct confirmed the predicted nucleotide sequence and length of the insert.
Competitive nested RT-PCR:
The primers for the nested competitor PCR are shown in Figure 1a and Table 1 . Table 2 Primer and probe sequences for AML1/MTG8 real-time PCR (Figure 1b )
One microliter of cDNA and 1 l of competitor DNA containing a defined number of competitor molecules were subjected to the first round of amplification in a 50 l reaction containing 1 × PCR buffer (Perkin Elmer, Foster City, CA, USA) with 1.5 mM MgCl 2 , 200 M of each dNTP, primers 0.2 M each and 1.25 U Taq DNA polymerase (Perkin Elmer). The first round of PCR was performed by an initial denaturation at 94°C followed by 35 cycles at 94°C for 1 min, 57°C for 1 min and 72°C for 2 min followed by a final extension step at 72°C for 10 min. Two microliters of the PCR product were subjected to the second PCR amplification in a 50 l reaction containing 0.4 M nested primers. The nested PCR was performed under the same conditions except that annealing was performed at 55°C for 2 min. 5 l of the second PCR products were electrophoresed on 2% agarose gels, stained with ethidium bromide and photographed. The amplification of the cabl transcript was used as a positive control. In negative controls, the RNA template was omitted. The length of the specific PCR products was 172 bp for wild-type AML1/MTG8 and 214 bp for the competitor.
Real-time PCR for AML1/MTG8
Real-time PCR:
The probe and primers for the AML1/MTG8 real-time PCR (Figure 1 b, Table 2 ) resulting in a 87 bp amplicon were designed with the PRIMER-EXPRESS software (Perkin Elmer). FAM (6-carboxyfluorescein) was used as the reporter and TAMRA (6-carboxy-tetramethylrhodamine) as the quencher dye. The reaction was carried out in 50 l with 1 × Taqman buffer A, 8.5 mM MgCl 2 , nucleotides 200 M, probe 150 nM, primers 300 nM each, 0.25 U AmpliTaq-Gold Polymerase (Perkin Elmer) and 1 l cDNA template. The reaction conditions were 95°C 10 min (activation of the AmpliTaq-Gold Polymerase) and then 40 cycles of 15 s 95°C (denaturation) followed by 60 s 59°C (annealing and extension). All experiments were carried out in triplicate and several negative controls were included. Fluorescence emission spectra were continuously monitored and analyzed by a SDS 7700 system (Applied Biosystems, Foster City, CA, USA) with the sequence detection software version 1.6.
AML1/MTG8 standard curve:
For the generation of the AML1/MTG8 standard curve, we used serial dilutions of the cloned 338 bp wild-type AML1/MTG8 PCR product and the cloned 380 bp DNA competitor molecule in RNAse free water. Both serial dilutions varied from 10 5 to 10 2 copies of the target molecule per microliter. All reactions including no template controls (NTC) were tested in triplicate. The standard curves were constructed and calculated by the sequence detector software version 1.6 referring the threshold cycle (PCR cycle at which a specific fluorescence becomes detectable, C T ) to the log of the copy number of each standard dilution step.
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Figure 2
Amplification of wild-type AML1/MTG8 (a) and the competitor molecule (b) by real-time PCR. The threshold cycle C T is plotted over the starting copy number of both target molecules. Both targets are amplified with the same efficacy and sensitivity.
Table 3
Quantification 
Real-time PCR for GAPDH
To compensate for differences in the RNA quality or RT efficacy in our Kasumi-1 dilution series, the expression of the housekeeping gene GAPDH was quantified with the GAPDH control reagents kit (Perkin Elmer) according to the manufacturer's guidelines. 
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Results
Comparison of competitor and wild-type AML1/MTG8 as a PCR template
A 1:1 mixture of wild-type AML1/MTG8 plasmid and the competitor plasmid over the range from 10 5 to 10 1 copies was subjected to both rounds of the nested RT-PCR. In all dilution steps both bands with 172 (wild-type AML1/MTG8) and 214 bp (competitor) could be clearly detected with similar intensity indicating that the affinity of the PCR primers is similar to both target molecules over a broad concentration range (Figure 1a) . Also, two dilution series of wild-type AML1/MTG8 and competitor molecule were amplified with real-time PCR (Figures 1b and 2) . Again, there was no marked difference in the C T values for the various dilution steps between wild-type AML1/MTG8 and competitor.
Sensitivity analysis of nested RT-PCR and real-time PCR
The sensitivity of our nested PCR was determined by a serial dilution of the cloned AML1/MTG8 sequence and the competitor molecule. Ten copies of both target molecules could be reliably detected by the nested PCR. Furthermore, using cDNA from the Kasumi-1 dilution series as a target, Kasumi-1 cells could be reliably detected with a sensitivity of 1:10 5 with the nested RT-PCR (Table 3) . Aliquots of the same templates were used for the analysis of the sensitivity of the realtime PCR assay. Again, the detection threshold was 10 copies of cloned AML1/MTG8 and competitor molecule and 1:10 5 for the Kasumi-1 dilution series respectively (Table 4 ). There was a linear decrease of the threshold cycle in proportion to the log of the starting copy number with a correlation coefficient of 0.97 to 0.99 in various repetitions of the experiment with all target molecules used.
Reproducibility and linearity of competitive nested PCR and real-time PCR
Our Kasumi-1 cellular dilution series from pure Kasumi-1 cells to one Kasumi-1 cell in 10 5 NB4 cells was used as a template to compare the reproducibility and linearity of the two PCR assays (Figure 3a and b) . GAPDH real-time PCR showed almost identical C T values (greatest difference Ͻ0.5; Figure 4 ) for cDNA aliquots from the different Kasumi-1 dilution steps indicating an accurate quantification of the RNA template before reverse transcription and a comparable efficacy of the RT reaction in the different tubes. Real-time PCR had the same sensitivity on the cellular level as the nested competitor RT-PCR. The quantitative results of competitor PCR compared very well to the quantification by real-time PCR and the results of both methods corresponded well to the dynamic range of each dilution step over the full five log range (Tables 3 and 4 ).
Figure 4
Amplification of GAPDH in the cDNA of the Kasumi-1 dilution series. The increase of the fluorescence (⌬R n ) is plotted against the PCR cycle. The aliquots of the different dilution steps show an almost identical threshold cycle (C T ) indicating an accurate quantification of the RNA and an equal efficacy of the RT reaction.
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Quantification of AML1/MTG8 in patient samples
AML1/MTG8 was analyzed in parallel by competitive PCR and real-time PCR in samples from three patients with t(8;21) positive AML at initial diagnosis and during/after chemotherapy (Figure 5a-c) . All three patients displayed a marked decline of AML1/MTG8 expression during chemotherapy and two patients even tested negative for real-time and competitive PCR after high-dose AraC consolidation therapy. Again, the results of real-time and competitive PCR favorably compared over a five log range and the reduction of the leukemic burden could be adequately quantified by both methods.
Discussion
In contrast to other chromosomal lesions, eg the PML/RAR␣ rearrangement in translocation t (15;17) , where the detection of the clone specific marker heralds the hematological relapse of the disease, 37 the prognostic significance of the persistence of AML1/MTG8 transcripts in hematological remission as detected by qualitative RT-PCR remains doubtful. Recent data indicate that the quantification of the amount of the AML1/MTG8 transcripts may be more predictive for the outcome than a nonquantitative assessment. [17] [18] [19] Competitive RT-PCR assays which are widely used for the quantification of leukemia specific fusion transcripts carry, however, a great risk of contamination due to the necessary post-PCR processing and are time-consumptive.
Recently, real-time RT-PCR which is based on the 5Ј-3Ј exonuclease activity of the Taq Polymerase and the use of fluorogenic DNA probes has been introduced. This technique has been used for the quantification of tumor specific DNA or RNA sequences in AML, CML, follicular lymphoma, multiple myeloma and childhood ALL. [27] [28] [29] [30] [31] Since competitive PCR and real-time PCR use different quantification strategies, ie coamplification of an internal standard vs standard curves generated by separate amplification of an external standard, both methods had to be systematically compared to evaluate if data generated by the different assays are superimposable. We therefore compared the sensitivity, linearity and reproducibility of both approaches using AML1/MTG8 plasmids and t(8;21) positive leukemic cells as a target. Some investigators recommend the use of RNA competitor molecules as internal standards for competitor PCR assays, because these may adjust differences in the efficacy of the reverse transcriptase reaction. 24, 38, 39 In contrast, we used a DNA competitor molecule as an internal standard. The quantitative assessment of the expression of the GAPDH housekeeping gene in our cDNA probes and the linearity and reproducibility of our data demonstrate that an accurate quantification of the RNA template before reverse transcription and a complete standardization of the RT reaction is sufficient to guarantee stable reaction conditions. Moreover, DNA standards are more resistant to degradation under storage conditions allowing the direct comparison of analyses over a longer period of time. In addition, the design and cloning of our competitor molecule allowed its use as an internal competitor, as well as an external standard molecule to establish a standard curve in the realtime PCR assay. As a consequence, both methods could be directly compared. As previously described for M. tuberculosis DNA 40 nested competitor PCR and real-time PCR had an identical sensitivity with a detection limit of 10 target molecules. In addition, AML1/MTG8 transcripts could be quantified over a dynamic range of five log steps by both techniques
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Figure 5
Quantification of AML1/MTG8 in patient samples: AML1/MTG8 was quantified in parallel by real-time and competitive PCR in cDNA of bone marrow samples from three patients with t(8;21) positive AML. The number of AML1/MTG8 copies in the samples is plotted against the various time points of analysis. The copy number quantified by real-time PCR is given in bold, the number estimated by competitive PCR in italics. When the equivalence point of the competitive PCR was between two competitor dilutions, the mean value of the two adjacent competitor dilutions is given. (a) Patient 1 was first analyzed at initial diagnosis (ID). On day 15 after induction chemotherapy (1) he had approximately 50% residual blasts but went into a partial remission on day 21 (2) . In aplasia after the second induction course (3) and after hematopoietic recovery (4), he displayed a further reduction in AML1/MTG8 expression and went into a complete remission. (b) Patient 2 tested positive for AML1/MTG8 at initial diagnosis (ID) and after completion of the induction chemotherapy (1). After high-dose AraC consolidation, AML1/MTG8 expression was below the detection level of real-time and competitive PCR (2) . (c) Patient 3 showed a two log reduction of AML1/MTG8 from initial diagnosis (ID) to complete remission after induction therapy and became PCR negative after high-dose AraC consolidation. and the data obtained favorably compared between the two assay systems. This was true not only for a serial dilution of plasmids and cell lines but also for samples from t (8;21) positive AML patients at different stages of their disease.
Recently several groups have demonstrated that chemotherapy can induce a decrease of AML1/MTG8 fusion transcripts over at least three log steps in t(8;21) positive AML patients. [17] [18] [19] Since both methods cover this clinically relevant range they both can be recommended for MRD analysis in a clinical setting.
Taken together, in our hands competitive RT-PCR and realtime PCR were equally sensitive and reproducible assays and data obtained by the different methods can be directly compared. Both methods can be recommended to monitor MRD in t(8;21) positive AML patients. However, due to its automatization real-time PCR offers the possibility to screen larger series of probes within a shorter period of time which is of advantage in MRD analyses, since large prospective studies are necessary to determine the prognostic relevance of quantitative MRD detection in this genetic AML subtype.
